The fact is, no one is truly safe until everyone is safe.

The mRNA UCV Consortium is formed for development and delivery of the mRNA Universal Coronavirus Vaccine.

NORVAX UK Limited* founded the mRNA UCV Consortium with the mission to develop and manufacture the mRNA Universal Coronavirus Vaccine (UCV) at industrial scale for COVAX Markets and HIC Markets for delivery in 2022/23 on Advance Purchase Agreements (APA) by sponsors, governments and industry customers. The vision of mRNA UCV Consortium is to help end the COVID-19 pandemic and to stimulate and support pandemic preparedness for future outbreaks.

The goal of the mRNA UCV in development by Norvax UK with Norsk Vaksinefabrikk (Norvax AS) and the mRNA UCV Consortium is to help solve the urgent global need for a one-time COVID-19 booster to save lives and help to end the COVID-19 pandemic and to support mRNA vaccine innovation for future pandemic preparedness.

Members of the mRNA UCV Consortium, and VaxComm – The Vaccine Commons, are openly supported to apply the mRNA Vaccine Platform by Norvax to develop safe and effective novel mRNA vaccines for infectious diseases, therapeutics and cancers.

*formerly named ECAM Vaccines Limited

mRNA UCV Consortium Map

Members of the mRNA UCV Consortium

Mmbers of the mRNA UCV Consortium

NORVAX UK Limited is the product developer and is leading the organization of the consortium and is the Secretariat for Vaxcomm the Vaccine Commons. NORVAX UK was founded by Peter A. Jensen, and is located in London, England. Mr. Jensen has 35+ years of biotech and business innovation in Norway, UK and US. Mr. Jensen is the founder and President & Chairman of Norsk Vaksinefabrikk by Norvax AS. Mr. Jensen is the founder of Vaxcomm the Vaccine Commons.

AmpTec (Merck) – Strategic mRNA Technology Partner, with Merck. TEAM-1 Member.
AmpTec is a leading international provider of RNA technology products, including RNA isolation and mRNA amplification kits, synthetic long RNAs and DNAs as well as functional mRNAs. We are committed to direct and flexible customer interactions with life science industries and academic research institutions around the world, including on-site technical support including: (1) High Quality Provider of IVT-RNAs since 1998, (2) Provider of synthetic Nucleic Acids for worldwide leading Companies in the field of molecular diagnostics and biotechnology, (3) Manufacturer in compliance with ISO 9001 since 2008, (4) Manufacturer in compliance with ISO 13485 since 2010. (5) Compliance with cGMP since 2012 (regulations of FDA 21 CFR Part 820), (6) Implementation of cGMP FDA 21 CFR Part 211 and ICH Q7 (section 19: APIs for use in clinical trials) requirements in advanced state (7) quality management system, certified by DQS MED. AmpTec has been acquired by Merck, a leading science and technology company, based in Germany.

Visit Website

Cytiva (formerly GE Healthcare) – Strategic Technology Vendor. DNA/RNA Upstream/Downstream Systems
Cytiva. Advancing the development and manufacture of therapeutics. Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. We have a rich heritage tracing back hundreds of years, and a fresh beginning since 2020. Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes. Cytiva is a global life sciences leader with over 7,000 associates across 40 sites who are dedicated to our vision to improve access to life-changing therapies that transform human health. As a trusted partner to customers that range in scale and scope, Cytiva brings efficiencies to research and manufacturing workflows, ensuring the development, manufacture and delivery of transformative medicines to patients. We operate in 40 countries and territories covering Europe, Asia, North and Latin America, and the Middle East. Our 7,000 associates are dedicated to our mission to advance and accelerate therapeutics. We host 11 customer-centered innovation facilities across Asia, Europe and the Americas to carry ideas through to commercial development.

Visit Website

eTheRNA – Strategic mRNA Technology Partner for this application. TEAM-1 Member.
eTheRNA. Advanced Technology Boosting Immunotherapy. eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases. We employ messenger RNA to unleash and boost a patient’s immune response against a tumor or infectious agent. Research shows that this approach results in long lasting clinical remission in cancer patients and protective immunity against infections. eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology. Key Milestones. 2015 -2018. (i) Spun out of Vrije Universiteit Brussel, a prominent university in the capital of Belgium, (ii) Establish core TriMix mRNA platform, (iii) Translational Phase I/II clinical studies. 2019 – 2021. (iv) GMP facility established, (v) Novel formulation, (vi) Establish product pipeline, (vii) Asia expansion. For the convenience of patients and practitioners, eTheRNA is working on an mRNA-formulation that can be administered needle-free, via intranasal administration.

Visit Website
Addressing your specific needs with cutting edge expertise. Our services are delivered by the world renowned research community at Imperial College London, supported by a dedicated professional services team who ensure your project is delivered on time and to specification. Over the last year, we’ve delivered 875 projects, for nearly 600 clients based in the UK and overseas.  With access to over 4000 leaders in their field, we can find the right consultant, with the right expertise to address your challenge…
Advisory services. Product design, research methods, data analysis, technology evaluation for investment, technological innovation, patent evaluation, prototype and protocol development, policy, cyber security and more. Assisting museums, writers, film makers and artists to ensure creations are scientifically sound.
Expert insight .Membership of Scientific Advisory Boards and Technical Panels, advice and guidance on drug development programmes, thought leadership, conference speakers, literature reviews and provision of foresight.
Analysis and testing. Use of the world-class specialist facilities and technicians at Imperial for projects ranging from aerodynamic measurements and medical imaging to structural testing and analysis.
Visit Website

IQVIA – Strategic Clinical Research Organization (CRO) Partner – Contractual
IQVIA. Driving healthcare forward. IQVIA is a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. Together with the companies we serve, we are enabling a more modern and effective healthcare system and creating breakthrough solutions that transform business and patient outcomes. IQVIA capabilities and expertise: (i) 1+ Billion Patient Identified Records, (ii) 72x faster data analytics using IQVIA human data science cloud, (iii) 40+ offerings; commercial offerings using artificial intelligence and machine based learning, (iv) 70,000 experts from clinicians to data scientists, serving customers in 100+ countries. In 2016, Quintiles and IMS Health came together to create something entirely new. IQVIA brings together advances in data science, technology, and human science expertise to help the healthcare industry make better decisions, and ultimately to improve patient outcomes. This vision for a healthier world, and the work we do to help the industry move forward, is why IQVIA is The Human Data Science Company™.

Visit Website

Knauer – Strategic Technology Vendor
Knauer Lipid Nanoparticle (LNP) production equipment. In connection with the development of mRNA-based vaccines against Corona, lipid nanoparticles (LNPs) have shown to be a suitable delivery form. LNPs encapsulate and protect the delicate active ingredient and allow its transport to the target cells in the human body. Corona vaccines are the first large-scale use of mRNA and lipid nanoparticles in vaccination history.

Visit Website

Merck KGaA – Strategic Technology Vendor. Lipid Catalog. DNA/RNA Upstream/Downstream Systems
Dedicated to human progress. Our purpose is to solve the toughest challenges in the life science industry in collaboration with the global scientific community. With our Research Solutions, Process Solutions, and Applied Solutions business units, we are a leading worldwide supplier of tools, high-grade chemicals, and equipment for academic labs, biotech, and biopharmaceutical manufacturers, as well as the industrial sector. Research Solutions provides our academic customers with the chemicals and biological tools needed to make scientific discovery easier and faster. Process Solutions provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing. Applied Solutions offers analytical workflows and both lab connectivity and digitization solutions to empower the labs of the future. Our passion for science and technology is what drives our 58,000 employees in 66 countries to find solutions to some of today’s toughest challenges and create more sustainable ways to live.

Visit Website

NEC OncoImmunity – Strategic Technology Service Partner. TEAM-1 Member.
NEC OncoImmunity AS is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy. NEC OncoImmunity AS is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in a clinically actionable time-frame. NEC OncoImmunity AS offers software solutions powered by a machine-learning engine that predicts from next generation sequencing data, true neoantigens for personalized cancer immunotherapy and cancer immunotherapy biomarkers, and for SARS-CoV-2.18 NEC OncoImmunity AS is a subsidiary of NEC Corporation, and is based in Oslo, Norway.

Visit Website

Norsk Vaksinefabrikk by Norvax AS – Contract Drug Manufacturing Organization (CDMO) Partner. TEAM-1 Member. Norsk Vaksinefabrikk is the developer of mRNA Vaccine Platform by Norvax and ECAM Vaccines. The First Vaccine Factory in Norway for Pandemic Preparedness. GMP/ISO Manufacturing of Vaccines, Therapeutics, and Diagnostics for COVID-19, Infectious Disease and Sustained Innovation in Pandemic Preparedness. OUR MISION. Serving the ecosystem as a partner for the transformative development and manufacture of vaccine and biological medicinal products. Norsk Vaksinefabrikk at Borgeskogen 65, Sandefjord. Norsk Vaksinefabrikk is located in the industrial park at Borgeskogen, Sandefjord, 12 minutes from TORP international airport for global access to sustainable biopharmaceutical export service products for COVID-19, infectious disease and global epidemic preparedness. With a focus on partnership and open science we are developing the future of biological medicines through shared scientific expertise, agility and innovation, for the COVID-19 pandemic and long-term sustained pandemic preparedness. Our vision is to create an ecosystem for biological medicines, ‘Norsk Vaksinefabrikk’, where research and development will co-exist with established GMP manufacturing. Production/logistics building with associated offices: 12,733 sqm. OUR GOAL. Opening up leading science, discovery and technology for global public health and pandemic preparedness. Norsk Vaksinefabrikk focus for 2021 is rapid long-term growth, achieved through short- and long-term pandemic strategies. Our manufacturing solutions support the current COVID-19 pandemic with an industrial scale infrastructure. We plan to deliver sustained pandemic preparedness through open science research and development in Norway. Norsk Vaksinefabrikk is commissioning and deploying in Sandefjord the most advanced vaccine fill-finish manufacturing system in Norway capable of 36,000 2R vials per hour. In a 10R vial, at 0.5ml per dose, Norsk Vaksinefabrikk capacity is planned to be up to 289,000,000 vaccine doses per month.

Visit Website

Norsk Regnesentral – Strategic R&D Partner. TEAM-1 Member.
Norsk Regnesentral (NR, Norwegian Computing Center) is a private, non-profit, independent research institute that carries out contract research in the areas of computer science, applied statistics and machine learning for a broad range of industrial, commercial, and public organisations in Norway, as well as internationally. It is Norway’s leading applied statistical institute and one of Europe’s largest non-university centres in this area. We have 85 researchers, and 70 of these works within the fields of statistical modelling, machine learning, deep learning and image analysis. Our main applications are finance and insurance, earth observation, climate and environment, health, management, image analysis and petroleum. Our work within health includes bioinformatics, cancer research, clinical trials (including vaccine trials), medical image analysis and infectious diseases in humans and in fish.

Visit Website

SINTEF – Strategic R&D Partner – Contractual. TEAM-1 Member.
SINTEF is one of Europe’s largest independent research organisations. Every year we carry out several thousand projects for customers large and small. For more than 70 years, SINTEF has developed solutions and innovation for society and customers all over the world. This is how we have become a world-leading research institute. AN INDEPENDENT RESEARCH INSTITUTE. 2,000 employees. 75 nationalities. 4,000 customers. We deliver innovation by developing knowledge and technologies that are brought into practical use. SINTEF is a broad, multidisciplinary research organisation with international top-level expertise in the fields of technology, the natural sciences, medicine and the social sciences. We conduct contract R&D as a partner for the private and public sectors, and we are one of the largest contract research institutions in Europe. Our vision is Technology for a better society. RESEARCH, TECHNOLOGY AND INNOVATION Biotechnology and nanomedicine are key enabling technologies for various sectors of society and multiple industries. The technology is used in development of pharmaceuticals, vaccines, biomaterials, enzymes, food, feed, chemicals and energy. SINTEF Industry has a strong operation in the fields of microbial molecular biology, bioprocess- and medical technology, biopolymers/polymers, biopharmaceuticals and nanomedicine, and is operating a state-of-the-art research infrastructure including advanced mass spectrometry.

Visit Website

Syntegon – Strategic Technology Vendor. Contractual (PO in process)
Syntegon is a leading provider of processing and packaging technology. As a highly trusted partner to the food and pharmaceutical industries we supply customers with intelligent and sustainable solutions worldwide. As the former Bosch Packaging Technology GmbH headquartered in Waiblingen (Germany) we supply a wide range of machinery, systems, and services. 6,000 associates at more than 30 locations in over 15 countries, provide industry-specific consulting, engineering expertise, and machinery services. The FLC 3000 is a reliable and pioneering solution for the safe, efficient filling and closing of vials and infusion bottles in pharmaceutical production. Pharmaceutical manufacturers all over the world appreciate its unique combination of flexibility and compact design as well as the large variety of different equipment. With its impressive processing range with filling volumes from 0.5 to 500ml, the FLC fulfills the demands of modern everyday production. The large range of filling volumes is achieved by only three sets of size parts with minimal changeover times. The FLC is equipped with a continuous transport system, providing the best conditions for a robust and gentle vial or bottle process. Servo controlled programs guarantee the necessary precision and reproducibility of motion sequences. The FLC sets standards for operator convenience and ergonomics. The entire machine can be operated from one side. Size parts can be changed without the usage of tools. With more than 450 installed machines the FLC is the best sold pharmaceutical filling and closing machine ever.

Visit Website

Tenden Lawfirm
Competence built on experience. Legal expertise alone is not sufficient but need to be combined with a commercial mindset and knowledge of the clients’ needs, challenges and opportunities. Our lawyers provide tailormade advise and support based on competence build on long-time gained experience. Terje Dahl Svendsen specialises in intellectual property, commercial contracts, technology and digitalisation/ICT and R&D. Dahl Svendsen also works with marketing law, and trade, service and distribution, and has a long-standing experience in these areas. Dahl Svendsen is a Master of Laws (LLM) from London School of Economics. Before joining Tenden, he worked in the law firm Schjødt in Oslo.

Visit Website

Watson-Marlow Fluid Technology Group (WMFTG) is the world leader in niche peristaltic pumps and associated fluid path technologies for the food, pharmaceutical, chemical and environmental industries. Comprising ten established brands, each with their own area of expertise, but together offering our customers unrivalled solutions for their pumping and fluid transfer applications.

Uniquely configurable Flexicon FPC60 fill/finish system offers production flexibility.

Watson-Marlow Fluid Technology Group has unveiled the new Flexicon FPC60 highly accurate peristaltic fill/finish system. A wide variety of modules are available for the system, allowing users to create their own bespoke filling solution to suit small-batch applications. The modules include vial infeed, filling, stoppering, capping, auto-reject, gas purging and product outfeed. Capable of handling vial sizes between 2R and 100H the FPC60’s unique servo-driven auto adjustment allows for minimal tools and quicker set-up between batches. Moreover, when supplied with in-line check weighing, the FPC60 offers unique dynamic prime, no-intervention initial calibration and dynamic recalibration, meaning every vial, from first to last, is confirmed to be within specification. With the addition of dynamic prime, users will benefit from no loss of valuable product.

Visit Website

We develop creative, comprehensive and sustainable engineering solutions for a future where society can thrive. Equipped with an intimate understanding of local intricacies, world-class talent and proactive leadership, we plan, design, manage and engineer long lasting and impactful solutions to uniquely complex problems. 

Visit Website

Vaxcomm
Vaxcomm is The Vaccine Commons for affordable access to modern vaccine technologies for the benefit of members and of the global public health commons. Vaxcomm is open to all members who support and engage the Vaxcomm commons principles and rules of the community.
Design principles for Common Pool Resource (CPR) institution. Ostrom identified eight “design principles” of stable local common pool resource management:

  1. Clearly defined (clear definition of the contents of the common pool resource and effective exclusion of external un-entitled parties)
  2. The appropriation and provision of common resources that are adapted to local conditions;
  3. Collective-choice arrangements that allow most resource appropriators to participate in the decision-making process;
  4. Effective monitoring by monitors who are part of or accountable to the appropriators;
  5. A scale of graduated sanctions for resource appropriators who violate community rules;
  6. Mechanisms of conflict resolution that are cheap and of easy access;
  7. Self-determination of the community recognized by higher-level authorities;
  8. In the case of larger common-pool resources, organization in the form of multiple layers of nested enterprises, with small local CPRs at the base level.
Visit Website